Are There Other Ways to Get Investigational Drugs?

February 18, 2017

Although the most common way for patients to get access to an investigational new drug is through a clinical trial, there are other avenues that physicians and patients can pursue. Expanded Access C...

Read more

How Do Patients Get Access to Investigational Drugs?

February 4, 2017

Investigational drugs can provide an avenue for patients to try new oncology drugs prior to the treatments completing the FDA approval process. FDA approval is the last step in the drug development pr...

Read more

Are Cancer Clinical Trials Just for Advanced Cancer?

January 27, 2017

Most people wanting to participate in cancer clinical trials are people suffering advanced cancer. Having depleted treatment options that failed to stop the progression of their cancer, these patients...

Read more

If I Enter a Cancer Clinical Trial, Is There a Chance I will Receive a Placebo Instead of Cancer Therapy?

January 13, 2017

Only when a cancer clinical trial involves people with treatment-resistant or progressive cancer would a placebo be given.  Participants are always informed they may receive a placebo prior to th...

Read more

What is a Placebo?

December 31, 2016

Cancer clinical trials rarely employ the use of placebos, or “sugar pills,” since participants typically suffer from a form of cancer that has resisted standard treatments and are searchin...

Read more

What Is the Difference Between Standard Therapy and Experimental Therapy in a Cancer Clinical Trial?

December 16, 2016

The U.S. Food and Drug Administration’s Center for Drug Evaluation and Research is responsible for ensuring all drugs marketed in the U.S. are effective and safe for human use. However, the CDER...

Read more

What Is Standard Therapy in Cancer Treatment?

December 2, 2016

Standard therapies for treating cancer include surgery, radiation therapy and chemotherapy, depending on the part of the body affected and stage at which the cancer is diagnosed. Solid tumors respond ...

Read more

TD2 Works Closely with ZIOPHARM Oncology to Conduct a Preclinical Study Presented at the Annual Society for Neuro-Oncology Meeting in Houston, TX

November 21, 2016

November 21, 2016 Ziopharm presents preclinical data generated by TD2; Local Regulated IL-12 Expression as an Immunotherapy for the Treatment of Pontine Glioma.  See attached poster....

Read more

What Is a Randomized Cancer Clinical Trial?

November 18, 2016

All clinical trials progress through levels—Phase I, Phase II and Phase III. Phase I of a clinical trial involves studying the new drug or treatment to discover a safe dose amount. Evaluation of...

Read more

Why Are Randomized Cancer Clinical Trials Important in Developing New Treatments for Cancer?

November 4, 2016

Used extensively in biological experiments and human clinical trials, randomization prevents both accidental and selection bias by eliminating sources of bias and producing comparable groups. Randomiz...

Read more

Where Do Cancer Clinical Trials Take Place?

October 21, 2016

Conducted in hospitals, veterans’ medical centers, university hospitals, medical clinics, cancer centers or physicians’ offices, cancer clinical trials test drugs, blood products, medical ...

Read more

What Is an Investigational Drug?

September 15, 2016

The development of a new drug is a long and involved process that requires months, if not years, of lab work and testing. However, if results are promising, the drug company or a sponsor can send a re...

Read more

TD2 to Present at the Upcoming 4th Annual Tumor Models in Boston

July 15, 2016

TD2's VP of Nonclinical Operations, Paul Gonzales, will be presenting at the upcoming 4th Annual Tumor Models - Boston (www.tumor-models.com) on Wednesday, July 20th.  The topic of the p...

Read more

TD2 Works Closely with ZIOPHARM Oncology to Conduct a Preclinical Study Being Presented at the Upcoming ASGCT Meeting in Washington, DC

April 28, 2016

April 28, 2016 Below is the abstract seelcted for presentation at the upcoming American Society of Gene & Cell Therapy 19th Annual Meeting:   Regulated Expression of IL-12 as Gene Therapy ...

Read more

TD2 and Navigating Cancer Partner to Bring Patient-Reported Outcomes to Clinical Trials Through a Cutting-Edge Mobile Application

April 20, 2015

Leading patient engagement and mobile care management solution and precision oncology CRO partner to revolutionize patient engagement in clinical trials Scottsdale, AZ and Seattle, WA – April 2...

Read more

Paradigm and TD2 Announce Strategic Partnership For Tumor Profiling Service

April 20, 2015

Collaboration to provide expanded use of Paradigm Cancer Diagnostic (PCDx™) service by oncologists across large oncology network SCOTTSDALE, AZ and ANN ARBOR, MI Monday, April 20, 2015 -- Parad...

Read more

Responsibility for Pancreatic Cancer Research Team Moves to Seattle Non-Profit Institution

September 10, 2014

Responsibility for Pancreatic Cancer Research Team Moves to Seattle Non-Profit Institution Seattle, WA. September 8, 2014   Seattle’s own Cancer Research And Biostatics (CRAB), a...

Read more

Inform Genomics and Translational Drug Development (TD2) Announce Strategic Collaboration

June 23, 2014

TD2 and Inform Genomics Announce Strategic Partnership BOSTON, June 23, 2014 (GLOBE NEWSWIRE) -- Inform Genomics, Inc., a privately held company that utilizes a proprietary technology platform to dis...

Read more

MPI and TD2 Join in Strategic Collaboration to Provide Drug Developers a Unique Multi Biomarker Direct Path to Drug Approval

April 3, 2014

MPI and TD2 Join in Strategic Collaboration to Provide Drug Developers a Unique Multi Biomarker Direct Path to Drug Approval Medical Prognosis Institute A/S (MPI) - a Danish company and Translational...

Read more

Nuvilex Selects Translational Drug Development (TD2) to Advance Treatment for Pancreatic Cancer

April 1, 2014

Nuvilex Retains TD2 to Conduct Preclinical and Clinical Studies SILVER SPRING, Apr 01, 2014 (GLOBE NEWSWIRE via COMTEX) -- Nuvilex, Inc. (otcqb:NVLX), a clinical-stage international biotechnolog...

Read more

Forma Therapeutics makes deal with Celgene potentially worth $600M

April 1, 2014

Forma Therapeutics makes deal with Celgene worth $600M Watertown biotech firm Forma Therapeutics has announced a collaboration with drug giant Celgene Corp. potentially worth $600 million over t...

Read more

Dr. Daniel D. Von Hoff named one of ASCO’s 50 Oncology Luminaries

March 10, 2014

Dr. Von Hoff's research led to development of numerous therapeutic agents, and improved patient care. In association with its 50th anniversary, the American Society of Clinical Oncology (ASC...

Read more

Translational Drug Development (TD2) attracts Dallas partner

December 18, 2013

ORIX USA brings investment dollars that will enable TD2 to expand; help grow Arizona’s biomedical economy SCOTTSDALE, Ariz., and DALLAS, Texas — Dec.18th, 2013 — ORIX USA Health and...

Read more

FORMA THERAPEUTICS ANNOUNCES ADVANCEMENT OF TUMOR METABOLISM COLLABORATION WITH JANSSEN

September 16, 2013

Ongoing Collaboration Advances as FORMA Therapeutics Receives Licensing Payment and Additional Research Funding WATERTOWN, Mass., July 9, 2013 – FORMA Therapeutics announced today the advanceme...

Read more

First-in-Human Thunder God Vine Trial-Minnelide

September 12, 2013

TGen and Scottsdale Healthcare launch Phase I 'Thunder God vine' trial for cancer First patient receives treatment at Virginia G. Piper Cancer Center Clinical Trials SCOTTSDALE, Ariz.&n...

Read more

FDA approves drug tested by Scottsdale Healthcare and TGen

September 6, 2013

Abraxane now part of standard-of-care for patients with advanced pancreatic cancer, following studies at the Virginia G. Piper Cancer Center at Scottsdale Healthcare SCOTTSDALE, Ariz., Sept.&nbs...

Read more

TGen-TD2-Scottsdale Healthcare breast cancer pilot study

July 17, 2013

TGen-TD2-Scottsdale Healthcare breast cancer pilot study shows value of molecular profiling and proteomic mapping Patients benefit from treatments tailored specifically for their tumor types; stage se...

Read more

Translational Drug Development (TD2) and 21Century Oncology Partner to Advance Radiation/Cancer Drug Combined Therapy

June 21, 2013

SCOTTSDALE, Ariz. – (June 19, 2013) – Cancer pharmaceutical development company, Translational Drug Development (TD2), and the Translational Research Consortium (TRC) t...

Read more

TD2 helps SideOut Foundation with the conduct of their trial

June 14, 2013

TD2 helps SideOut Foundation with the conduct of their trial Article written by: Michele McDonald at George Mason University Funded by volleyball teams nationwide, a new study released this week show...

Read more

Pancreatic Cancer Research Team (PCRT) celebrates its 10-year anniversary of delivering new treatments for patients with pancreatic cancer

May 30, 2013

Ten Years after its founding, the Pancreatic Cancer Research Team (PCRT) is announcing the positive results of a large Phase III clinical trial involving more than 800 patients. PCRT is celebrati...

Read more

TD2 is the development partner for the FORMA/Celgene partnership

April 29, 2013

TD2 is the development partner for the FORMA/Celgene partnership WATERTOWN, Mass. – April 29, 2013 – FORMA Therapeutics Holdings, LLC (FORMA) today announced a strategic collaboratio...

Read more

Forma Therapeutics teams with TD2

June 18, 2012

Organizational synergies will create transformative cancer therapies June 18, 2012 - FORMA Therapeutics and TGen Drug Development (TD2) today announced an agreement to jointly develop transformative ...

Read more

Flagship Biosciences finds Arizona a great home for serving pathology digitally

June 5, 2012

While most of Flagship’s customers are at biotech and pharma locations around the world, there has been some strong collaborations formed with Arizona biotech firms. “The collaboratio...

Read more

CytRx Initiates Phase 2 Clinical Trial with INNO-206 in Pancreatic Cancer

May 31, 2012

Daniel Von Hoff, M.D., Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGEN) in Phoenix will serve as the clinical trial’s principal investigator...

Read more

TGen Drug Development (TD2) partnership with Imaging Endpoints provides comprehensive clinical trial services for drug developers

August 25, 2011

TGen Drug Development (TD2) and Imaging Endpoints have teamed up to enable the rapid development of anti-cancer drugs and deliver them faster to patients in need, the companies announced today.  ...

Read more

Avantra Biosciences

August 11, 2011

Avantra Biosciences teams with TGen Drug Development to assist pharma...

Read more